The RIQAS CYFRA 21-1 Proficiency Testing programme is designed to cover the analysis of CYFRA 21-1 in clinical laboratories when monitoring the response to treatment of cancers such as non-small cell lung carcinoma, cervical, breast and bladder cancer.
Lyophilised material for enhanced stability
World's largest PT scheme ensures peer groups are maximised
Monthly reporting for earlier identification of test system errors